Wright JA - Search Results

1

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. Desai AA, et al. Among authors: wright ja. Ann Oncol. 2005 Jun;16(6):958-65. doi: 10.1093/annonc/mdi178. Epub 2005 Apr 11. Ann Oncol. 2005. PMID: 15824081 Free article. Clinical Trial.

2

GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.

Lee Y, Vassilakos A, Feng N, Jin H, Wang M, Xiong K, Wright J, Young A. Lee Y, et al. Int J Oncol. 2006 Feb;28(2):469-78. Int J Oncol. 2006. PMID: 16391803

3

GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A. Lee Y, et al. Cancer Res. 2003 Jun 1;63(11):2802-11. Cancer Res. 2003. PMID: 12782585

4

Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin.

Lee Y, Vassilakos A, Feng N, Avolio T, Jin H, Viau S, Wang M, Courssaris B, Xiong K, Wright J, Young A. Lee Y, et al. Anticancer Drugs. 2006 Feb;17(2):143-54. doi: 10.1097/00001813-200602000-00005. Anticancer Drugs. 2006. PMID: 16428932

5

Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.

Ferdinandi ES, Vassilakos A, Lee Y, Lightfoot J, Fitsialos D, Wright JA, Young AH. Ferdinandi ES, et al. Among authors: wright ja. Cancer Chemother Pharmacol. 2011 Jul;68(1):193-205. doi: 10.1007/s00280-010-1473-z. Epub 2010 Oct 1. Cancer Chemother Pharmacol. 2011. PMID: 20886212

6

GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.

Vassilakos A, Lee Y, Viau S, Feng N, Jin H, Chai V, Wang M, Avolio T, Wright J, Young A. Vassilakos A, et al. Int J Oncol. 2009 Jan;34(1):33-42. Int J Oncol. 2009. PMID: 19082475

7

Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.

Feng N, Jin H, Wang M, Du C, Wright JA, Young AH. Feng N, et al. Among authors: wright ja. Cancer Chemother Pharmacol. 2003 Mar;51(3):247-55. doi: 10.1007/s00280-002-0559-7. Epub 2003 Mar 5. Cancer Chemother Pharmacol. 2003. PMID: 12655444

8

Macrophages play a critical role in the anti-tumor activity of Virulizin.

Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, Young AH. Du C, et al. Among authors: wright ja. Int J Oncol. 2003 Nov;23(5):1341-6. Int J Oncol. 2003. PMID: 14532975

9

Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models.

Du C, Feng N, Jin H, Wang M, Wright JA, Young AH. Du C, et al. Among authors: wright ja. Anticancer Drugs. 2003 Apr;14(4):289-94. doi: 10.1097/00001813-200304000-00006. Anticancer Drugs. 2003. PMID: 12679733

10

Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.

Cao MY, Lee Y, Feng NP, Xiong K, Jin H, Wang M, Vassilakos A, Viau S, Wright JA, Young AH. Cao MY, et al. Among authors: wright ja. Clin Cancer Res. 2003 Oct 1;9(12):4553-61. Clin Cancer Res. 2003. PMID: 14555530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

602 results

Search Page

Filters